Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · IEX Real-Time Price · USD
1.730
+0.020 (1.17%)
At close: Jul 19, 2024, 4:00 PM
1.740
+0.010 (0.58%)
Pre-market: Jul 22, 2024, 6:46 AM EDT
Palatin Technologies Revenue
Palatin Technologies had revenue of $5.90M in the twelve months ending March 31, 2024, with 52.80% growth year-over-year. In the fiscal year ending June 30, 2023, Palatin Technologies had annual revenue of $4.85M with 230.53% growth.
Revenue (ttm)
$5.90M
Revenue Growth
+52.80%
P/S Ratio
4.73
Revenue / Employee
$173,589
Employees
34
Market Cap
27.92M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
Jun 30, 2022 | 1.47M | 1.66M | -878.62% |
Jun 30, 2021 | -188.60K | -306.59K | -259.84% |
Jun 30, 2020 | 117.99K | -60.18M | -99.80% |
Jun 30, 2019 | 60.30M | -6.83M | -10.18% |
Jun 30, 2018 | 67.13M | 22.41M | 50.11% |
Jun 30, 2017 | 44.72M | - | - |
Jun 30, 2016 | 0 | - | - |
Jun 30, 2015 | 12.95M | - | - |
Jun 30, 2014 | 0 | - | - |
Jun 30, 2013 | 10.36K | -63.38K | -85.95% |
Jun 30, 2012 | 73.74K | -1.40M | -95.00% |
Jun 30, 2011 | 1.48M | -12.71M | -89.60% |
Jun 30, 2010 | 14.18M | 2.83M | 24.92% |
Jun 30, 2009 | 11.35M | -131.51K | -1.15% |
Jun 30, 2008 | 11.48M | -2.92M | -20.29% |
Jun 30, 2007 | 14.41M | -5.34M | -27.05% |
Jun 30, 2006 | 19.75M | 1.79M | 9.98% |
Jun 30, 2005 | 17.96M | 15.64M | 675.64% |
Jun 30, 2004 | 2.32M | 1.05M | 82.29% |
Jun 30, 2003 | 1.27M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPTN News
- 4 weeks ago - Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds - PRNewsWire
- 4 weeks ago - Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) - PRNewsWire
- 5 weeks ago - Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity - PRNewsWire
- 2 months ago - Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 - PRNewsWire
- 2 months ago - Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity - PRNewsWire
- 2 months ago - Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 - PRNewsWire
- 3 months ago - Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 - PRNewsWire